Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis (Q34983894)

5 August 2017

1 reference

title

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis (English)

1 reference

5 August 2017

Neisseria meningitidis

1 reference

Richard Arnold

3

0 references

Diana Rae Martin

series ordinal

2

object named as

Diana Martin

1 reference

5 August 2017

5

Philipp Oster

1 reference

5 August 2017

6

Jane O'Hallahan

1 reference

5 August 2017

7

Einar Rosenqvist

1 reference

5 August 2017

Johan Holst

1

1 reference

5 August 2017

Concepcion Campa Huergo

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

28 May 2009

1 reference

5 August 2017

1 reference

5 August 2017

27 Suppl 2

1 reference

5 August 2017

B3-12

1 reference

The natural history of meningococcal carriage and disease

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

7 January 2021

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Population-based analysis of meningococcal disease mortality in the United States: 1990-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

A surveillance network for meningococcal disease in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Exploring the proteome of meningococcal outer membrane vesicle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Can nonliving nasal vaccines be made to work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Serogroup B meningococcal disease: new outbreaks, new strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

MeNZB vaccine and epidemic control: when do you stop vaccinating?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Henoch-Schönlein purpura and meningococcal B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

7 January 2021

inferred from DOI database lookup

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

7 January 2021

inferred from DOI database lookup

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.071

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2009.04.071

1 reference

release_xj72bbl3yzgkppwdj2wxw26e7e

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xj72bbl3yzgkppwdj2wxw26e7e

24 November 2022

mapped directly with Wikidata item

1 reference